Navigation Links
Inotek Pharmaceuticals Announces Publication of Animal Data from,Study of PARP Inhibition as Potential Preventative of Brain Injury,Following Stroke

BEVERLY, Mass.--(BUSINESS WIRE)--Apr 10, 2007 - Inotek Pharmaceuticals Corporation announced today the publication in the journal Stroke of preclinical animal data showing that the administration of a poly(ADP-Ribose) polymerase (PARP) inhibitor has a large protective effect on the survival of certain brain cells following a stroke. PARP is a nuclear enzyme that directs the repair of damaged DNA via the activation and recruitment of DNA repair enzymes and has potential applications for the treatment of cardiovascular conditions, oncology, and inflammatory disorders.

In the study, researchers from Professor Raymond Swanson's team at the University of California, San Francisco examined the use of a PARP inhibitor, PJ34, in a rat model of cerebral ischemia-reperfusion. Ischemia is a restriction in blood supply to a tissue, whereas reperfusion injury refers to tissue damage caused when blood supply is returned to that tissue. Rats were subjected to 10 minutes of cerebral ischemia and then treated with PJ34 or placebo (saline) for seven days beginning eight hours after the onset of reperfusion.

Researchers measured the activation of brain macrophages, known as microglial cells, at several time-points between 0 and 14 days following ischemia. Microglial activation is an important component of the brain's inflammatory response and precedes neuronal death. Rats treated with PJ34 exhibited near-complete suppression of microglial response after 5 days, and similar responses were also observed at other timepoints. At 7 days post-ischemia, neuronal survival was evaluated. PJ-34 reduced neuronal death in the CA1 hippocampus region by 84% in treated rats relative to control rats.

"We now have support for PARP inhibition as a potential method of suppressing brain inflammation and preventing injury following ischemia-reperfusion," said Andrew Salzman, M.D., President and Chief Executive Officer of Inotek. "These results support our earlier preclinical data which suggested that PARP inhibition therapy had activity when introduced late in the course of ischemia reperfusion to the animal brain. This may have particular relevance to the clinical setting where it is often impossible to treat patients early in the course of acute stroke."

These data were published by Professor Raymond A. Swanson of the University of California, San Francisco and the Veterans Affairs Medical Center, San Francisco in the February 2007 issue of Stroke (Vol. 38 (part 2), pages 632-6).

About PARP Inhibitors

Poly (ADP-ribose) polymerase (PARP) is an abundant nuclear enzyme that mediates the repair of DNA single strand breaks through the activation and recruitment of DNA repair enzymes. PARP's role in the inflammatory response may result from its ability to potentiate the activity of key inflammatory transcription factors (NF-kappaB and AP-1). PARP inhibitors have shown promise in a variety of inflammatory and ischemia/reperfusion diseases, including those related to acute cardiovascular conditions. PARP inhibitors may also have potential application in cancer, and are being studied to ascertain their ability to block one of the key defense mechanisms that cancer cells rely upon to resist standard chemotherapy. By blocking tumor defenses, PARP therapy may increase the susceptibility of tumors to standard chemotherapy or even reverse tumor resistance.

About Inotek Pharmaceuticals

Inotek Pharmaceuticals Corporation (www.inotekcorp.com) is a Phase 2, drug-development company with a deep pipeline of small molecule compounds targeting the key biological processes involved in cell survival and tissue injury. Inotek's three platform programs have resulted in six novel molecules in various stages of preclinical and clinical development that target: 1) PARP, a nuclear enzyme that is fundamental to DNA repair and inflammation; 2) peroxynitrite, a highly toxic oxidative and nitro sative species produced by cells in response to injury; and 3) the purinergic receptor family, with a specific focus on adenosine receptors.

Inotek was founded in 1996 and currently has 140 employees, located in its corporate headquarters and main research laboratories in Beverly, Massachusetts and its clinical operations and GMP production facilities in Israel. Inotek has developed integrated capabilities from early discovery through Phase 2 clinical development.

Contact

Inotek Pharmaceuticals Corporation
Jeffrey T. Walsh, 978-201-9129
Chief Business Officer
jwalsh@inotekcorp.com
or
MacDougall Biomedical Communications, Inc.
Kari Watson, 508-647-0209
Vice President
kwatson@macbiocom.com


'"/>




Related medicine technology :

1. Inotek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for INO-1001 at ACC Demonstrating PARP Inhibition and Anti-inflammatory Activity in Plasma of Patients Undergoing Primary Percutaneous Coronary Intervention
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
(Date:6/23/2016)... 2016  Experian Health, the healthcare industry ... patient payment and care experience, today announced ... and services that will enhance the breadth ... These award-winning solutions will enable healthcare professionals ... in an ever-changing environment and redefine front-office ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star ... , Millions of individuals in the United States and Canada wear eyeglasses. Once considered ... both correct vision and make a fashion statement. Even celebrities use glasses as a ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
Breaking Medicine News(10 mins):